PMID- 29671334
OWN - NLM
STAT- MEDLINE
DCOM- 20190405
LR  - 20190405
IS  - 1440-1665 (Electronic)
IS  - 1039-8562 (Linking)
VI  - 26
IP  - 4
DP  - 2018 Aug
TI  - Alzheimer disease: Non-pharmacological and pharmacological management of 
      cognition and neuropsychiatric symptoms.
PG  - 358-365
LID - 10.1177/1039856218766123 [doi]
AB  - OBJECTIVES: This clinical update review focuses on the management of cognition 
      and the neuropsychiatric features of Alzheimer's disease (AD) and highlights 
      current issues regarding pharmacological and non-pharmacological treatment, 
      putative therapeutics and recent relevant research findings in this area. 
      CONCLUSIONS: AD is a neurodegenerative progressive condition characterised by 
      cognitive impairment and functional decline. Most people with AD will demonstrate 
      neuropsychiatric features, better known as behavioural and psychological symptoms 
      of dementia (BPSD). Early recognition and treatment of BPSD are essential, as 
      these cause considerable distress and carer burden. While there are many 
      disease-modifying therapies for the cognitive symptoms still in the research 
      stage, only symptomatic treatments are currently available for these and the 
      BPSD.
FAU - Loi, Samantha M
AU  - Loi SM
AUID- ORCID: 0000-0002-4953-4500
AD  - Neuropsychiatrist, Department of Psychiatry, University of Melbourne and 
      NorthWestern Mental Health, Parkville, VIC, Australia.
FAU - Eratne, Dhamidhu
AU  - Eratne D
AD  - Neuropsychiatrist, Melbourne Neuropsychiatry Centre, University of Melbourne and 
      NorthWestern Mental Health, Parkville, VIC, Australia.
FAU - Kelso, Wendy
AU  - Kelso W
AD  - Neuropsychologist, Melbourne Neuropsychiatry Centre, University of Melbourne and 
      NorthWestern Mental Health, Parkville, VIC, Australia.
FAU - Velakoulis, Dennis
AU  - Velakoulis D
AD  - Neuropsychiatrist, Melbourne Neuropsychiatry Centre, University of Melbourne and 
      NorthWestern Mental Health, Parkville, VIC, Australia.
FAU - Looi, Jeffrey Cl
AU  - Looi JC
AUID- ORCID: 0000-0003-3351-6911
AD  - Neuropsychiatrist, Melbourne Neuropsychiatry Centre, University of Melbourne, 
      Parkville, VIC, and; Academic Unit of Psychiatry and Addiction Medicine, 
      Australian National University Medical School, Canberra, ACT, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180419
PL  - England
TA  - Australas Psychiatry
JT  - Australasian psychiatry : bulletin of Royal Australian and New Zealand College of 
      Psychiatrists
JID - 9613603
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Alzheimer Disease/complications/drug therapy/*therapy
MH  - Antipsychotic Agents/*therapeutic use
MH  - Behavioral Symptoms/drug therapy/etiology/*therapy
MH  - Cholinesterase Inhibitors/*therapeutic use
MH  - Excitatory Amino Acid Antagonists/*therapeutic use
MH  - Humans
MH  - Neuroprotective Agents/*therapeutic use
MH  - Psychiatric Rehabilitation/*methods
OTO - NOTNLM
OT  - alzheimer's disease
OT  - behavioural and psychological symptoms of dementia
OT  - neuropsychiatric symptoms
OT  - psychiatry
EDAT- 2018/04/20 06:00
MHDA- 2019/04/06 06:00
CRDT- 2018/04/20 06:00
PHST- 2018/04/20 06:00 [pubmed]
PHST- 2019/04/06 06:00 [medline]
PHST- 2018/04/20 06:00 [entrez]
AID - 10.1177/1039856218766123 [doi]
PST - ppublish
SO  - Australas Psychiatry. 2018 Aug;26(4):358-365. doi: 10.1177/1039856218766123. Epub 
      2018 Apr 19.